Idis Named Patient Programme Post Clinical Trial

Consulting with Idis to develop an Idis Named Patient Programme Post Clinical Trial will:

• Help you to allow patients to continue treatment with the investigational drug once your clinical trial has ended
• Enable you to manage risks associated with providing continued access post clinical trial
• Provide you with consolidated information which can be used to mitigate future risks

When a clinical trial comes to an end:

• What happens to patients who have responded well to the treatment?
• How can they continue to receive the drugs they desperately need?

Pharmaceutical and biotech companies have a responsibility to act ethically in these situations, but must also think about how such situations can affect their drug’s development.

By consulting with Idis, we can develop an Idis Named Patient Programme Post Clinical Trial to provide a lifeline to such patients, ensuring they can continue to receive the treatment they need while helping you to manage any risks associated with providing continued access.

An Idis Named Patient Programme Post Clinical Trial will help you minimise any risks associated with providing continued access to drugs after a trial’s conclusion, while showing you how to apply the programme to each individual patient once they come to the end of the study.

As market leaders in our field we're highly experienced in managing programmes for a diverse range of drugs in many different therapeutic areas. In particular, we have extensive knowledge in the area of oncology. In fact, no other company has launched more oncology products than Idis.

By consulting with Idis, you can rest assured that whatever your needs and whatever your therapeutic area, we will have a solution to suit you.

Idis Named Patient Programmes are regulatory compliant in all countries. We have the consultancy expertise to design and create even the most complex programmes and we take care of every regulatory detail, ensuring peace of mind.

We also provide expert advice in countries where the regulatory infrastructure is less well defined.